Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

ALX Oncology Holdings Inc. ALXO

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$-101.7M
$-84.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2022 · Revenue 0.0 · Net income -123.5
-50M-100M
2018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2020 · Operating -3694.0% · Net ·
-1000%-2000%-3000%
201820212025
ROE
FY2025 · ROE -145.7%
-50%-100%
201820212025
Three returns, three denominators.

Each USD of equity lost 146 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -84.4
-50M-100M
201820212025
Net buybacks $ Dividends $
FY2018 · Dividends · · Net buybacks -1000.0
-500-1000
2018

Total assetsUSD 59.0M
EquityUSD 26.0M
CashUSD 16.4M
Gross debtUSD 9.7M
Net debtUSD -6.6M
Current ratio2.07×

The company holds more cash than debt.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ALXO, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B◌◌◌0.00.00.00.00.0
Operating income $B−0.1−0.1−0.2−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.2−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.0−0.00.00.00.0
Net income $B−0.1−0.1−0.2−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−1.90−2.58−3.74−3.03−2.07−2.76−7.56−6.33
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %−145.7−88.9−71.0−39.4−21.1———
Shares out B0.050.050.050.040.040.040.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 11 checks were skipped: EPS is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image